| P210 | PD-1-positive tumor-infiltrating lymphocytes (TIL) for the next generation of adoptive T cell therapy | Michelle R. Abelson, PhD; Kenneth D'Argio; Angel Cedano-Hilton; Ian Frank; Krit Ritthipichai, DVM, PhD; Cecile Chartier; Michelle R. Abelson, PhD; | Adoptive immunotherapy; Clinical study; Inflammation; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P211 | Oxygen and pressure promote primary T cell expansion and can regulate population dynamics and cytokine release | Yunmin Li, Ph.D; Zachary Pappalardo; Mauricio Montano; Ann Lu; Bruce Adams | Adoptive immunotherapy; Cytokine; T cell; Tumor microenvironment |
| P212 | Preinfusion product doubling time is associated with CAR T cell expansion and outcomes in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma | Frederick L. Locke, MD; John M. Rossi, MS; Caron Jacobson, MD; David Miklos, MD; Armin Ghobadi, MD; Olalekan O. Oluwole, MBBS, MPH; Lazaros J. Lekakis, MD; Patrick Reagan, MD; Yizhou Jiang, PhD; Lianqing Zheng, PhD; William Go, MD, PhD; Adrian Bot, MD, PhD; | Adoptive immunotherapy; CAR T cells; Clinical study; Clinical trial; Leukemia/Lymphoma; Targeted therapy |
| P213 | CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule | Sophie AGAUGUE, PhD; Alexandre E. Michaux, PhD; Eytan Breman, MSc; Sebastien Mauen, PhD; David E. Gilham, PhD | Adoptive immunotherapy; CAR T cells; Solid tumors |
| P214 | Development of allogeneic gene-edited CAR T-cells: from preclinic to clinical proof of concept | Beatriz Aranda Orgilles, PhD; Agnes Gouble; Roman Galetto, PhD; Julianne Smith; Philippe Duchateau; David Sourdive; Laurent Poirot, PhD; Stephane depil | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Solid tumors; T cell |
| P215 | Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15 | Philip D. Bardwell, PhD; Elena Geretti; Xiaoyan Liang; Santina Caruso; De-Kuan Chang, Ph.D; Jesse Lyons; Carlos Tassa; Sanela Bilic; Janice Lanista; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Thomas L. Andresen, PhD | Adoptive immunotherapy; Cytokine; Immune toxicity; Solid tumors; T cell |
| P216 | Select metabolic and costimulatory bolt-on transgenes enhance chimeric receptor-bearing T cell activity against solid tumors | Luke Barron, Ph.D.; Kathleen Whiteman; Madaline Gilbert; Tapasya Pai; Megan Snyder, BS; Michael Fray; Allison Nelson; Tyler Johnson; Kelsey Lakeman; John Shin; Ryan Boomer; Seth Ettenberg; Kathleen McGinness; Greg Motz | Adoptive immunotherapy; CAR T cells; Costimulation; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| P217 | Small molecule control of inducible MyD88/CD40 regulates Natural Killer cell expansion and anti-tumor activity | Joseph H. Bayle; Xiaomei Wang, PhD; Wei-Chun Chang, PhD; Daniel J. Jasinski, PhD; Jan L. Medina; Aaron E. Foster, PhD; David M. Spencer, PhD; | Adoptive immunotherapy; CAR T cells; NK/NK T cell; Targeted therapy |
| P218 | Endogenous DAP10 provides optimal co-stimulation to NKG2D-based CAR T cells | Jennifer Bolsée; Eytan Breman, MSc; Thuy Nguyen; Sophie AGAUGUE, PhD; David E. Gilham, PhD | Adoptive immunotherapy; CAR T cells; Costimulation |
| P219 | SQZ’ing cells to engineer next generation antigen presenting cell (APC) therapies | Matthew G. Booty, PhD; Scott M. Loughhead; Kelan A. Hlavaty; Ildefonso Vicente-Suarez; Katarina Blagovic, PhD; Melissa Myint; Brittany Stokes, MS; Defne Yarar; Howard Bernstein, MD, PhD; Armon Sharei | Adoptive immunotherapy; Antigen presenting cells; Immune adjuvant; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P220 | Generating allogeneic CAR T cells without gene editing | Simon Bornschein, PhD; Alexandre E. Michaux, PhD; Susanna Raitano, PhD; Eytan Breman, MSc; Céline Jacques-Hespel; Fanny Huberty; Laura Saerens; Dorothée Daro; Steven R. Lenger, Ph.D.; Hidevaldo B. Machado, PhD; Jonathan D. Moore, PhD; Sophie AGAUGUE, PhD; David E. Gilham, PhD; | Adoptive immunotherapy; CAR T cells; Gene expression; T cell |
| P221 | The co-expression of a single shRNA targeting MICA and MICB with a NKG2D-CAR (CYAD-01) generates CAR-T cells resistant to target driven fratricide and improves CYAD-01 cell persistence in vivo | Simon Bornschein, PhD; Susanna Raitano, PhD; Jérôme Marijsse; Dorothée Daro; Steven R. Lenger, Ph.D.; Hidevaldo B. Machado, PhD; Jonathan D. Moore, PhD; Sophie AGAUGUE, PhD; David E. Gilham, PhD | Adoptive immunotherapy; CAR T cells; Gene expression; T cell; Targeted therapy; Tumor antigens |
| P222 | Genetic engineering of tumour infiltrating lymphocytes (TIL) with a novel recombinant growth factor receptor for treatment of solid tumours | John S. Bridgeman, BSc, MSc, PhD; Michelle L. Le Brocq; Joanne McCaffrey; Tania Katopodi, PhD; Gemma L. Owens, MB BCh, BSc, MRes; Aysha Patel; Ryan Guest; Robert E. Hawkins; | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P223 | In vitro analysis of Tumour Infiltrating Lymphocytes engineered with costimulatory antigen receptors delivering targeted costimulation | John S. Bridgeman, BSc, MSc, PhD; Michelle L. Le Brocq; Aysha Patel; Martina Sykorova; Tania Katopodi, PhD; Joanne McCaffrey; Ryan Guest; Robert E. Hawkins | Adoptive immunotherapy; Granulocyte; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P224 | Adoptive cell therapy using tumor infiltrating lymphocytes for the treatment of bladder cancer | Brittany Bunch, PhD; Matthew Beatty, PhD; Jennifer Morse, MS; Michael Kidd; MacLean Hall; Autumn Joerger; Charles C. Peyton; Mayer N. Fishman, MD, PhD; Amod A. Sarnaik, MD; Michael Poch; Shari A. Pilon-Thomas, PhD | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P225 | Adoptive cell transfer with NY-ESO-1 specific TCR T cells (TBI-1301) results in persistence, cytokine release syndrome and anti-tumor activity | Marcus O. Butler, MD; Valentin Sotov; Megan Nelles; Sarah Boross-Harmer; Luisa Bonilla; Sawako Elston; Michael Fyrsta; Diana Gray, MSc; Abha Gupta; Sevan Hakgor; Ausmeema Hossain; Michael X. Le; Darya Lemiashkova; Diane Liu; Charlotte S. Lo; Mark Comacho; Aaron Hansen; David Hogg, MD, FRCPC; Habeeb Majeed; Kiichi Murakami; Jessica Nie; Marc Ouellette; Albiruni R. Razak; Kendra Ross; Adrian Sacher, MD; Sam Saibil; Elizabeth Scheid; Anna Spreafico, MD PhD; Brendan Van As; Jennifer Y. Yam; Pamela S. Ohashi, PhD; Shuichi Takahashi; Shinya Tanaka; Linh Nguyen, PhD; Naoto Hirano, MD, PhD | Adoptive immunotherapy; Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| P226 | DeepTM IL-15 primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells | Shawn P. Carey, PhD; Beth Pearce; Darren Smith; Pengpeng Cao, PhD; Christine M. McInnis, PhD; Amy M. Shaw; Jonas Bruun, PhD; FABIO FACHIN, PhD; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Thomas L. Andresen, PhD; Andy Rakestraw, PhD; | Adoptive immunotherapy; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P227 | Tethering IL-12 to the surface of T cells induces a broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities | De-Kuan Chang, Ph.D; Gulzar Ahmad; Jonathan Nardozzi, PhD.; Thomas L. Andresen, PhD; Douglas Jones, PhD | Adoptive immunotherapy; Cytokine; Solid tumors; T cell |
| P228 | Novel electroporation method for T cells enables quick CAR-T cell manufacture | Jian Chen, PhD; Xiaofeng Xia, PhD | CAR T cells; Gene expression |
| P229 | Adapter mediated transduction with lentiviral vectors: A novel tool for cell-type specific gene transfer | Nicole Cordes, Master of Science; Carolin Kolbe; Thomas Schaser; Andrew Kaiser; | Adoptive immunotherapy; CAR T cells; Gene expression; T cell; Targeted therapy |
| P230 | Identification of CD4+ and CD8+ T lymphocyte-epitopes from the cancer testis antigen Lactate dehydrogenase C | Hibah Shaath; Remy Thomas; Salman M. Toor; Eyad Elkord, PhD; Julie Decock, PhD; | Adoptive immunotherapy; Biomarkers; T cell; Targeted therapy; Tumor antigens |
| P231 | Uncovering the phenotype, the functional and homing properties of NKG2D CAR T cells | Benjamin Demoulin; Eytan Breman, MSc; Sophie AGAUGUE, PhD; David E. Gilham, PhD; Panagiota Sotiropoulou, PhD; | CAR T cells; Chemokine; Leukemia/Lymphoma; T cell; Targeted therapy |
| P232 | Differential effects of target ligands upon NKG2D CAR T cell activation. | Eytan Breman, MSc; Martina Fontaine, PhD; Nancy Ramelot; Sophie AGAUGUE, PhD; David E. Gilham, PhD; Panagiota Sotiropoulou, PhD | CAR T cells; T cell; Targeted therapy; Tumor antigens |
| P233 | CD8+ tumor-infiltrating lymphocytes expanded from a NSCLC immunosuppressive environment display neoantigen-specific recognition | Lorenzo Federico, PhD; Andrea Ravelli; Cara Haymaker, PhD; Marie-Andrée Forget, Ph.D.; Tatiana Karpinets, MS; Jason Roszik, PhD; Donastas Sakellariou-Thompson, BS; Young Uk Kim, PhD; Ankit Bhatta, MSc; May Celestino, BS, MA; Alexandre Reuben; Annikka Weissferdt; Ara A. Vaporciyan, MD; Mara B. Antonoff, MD; Garret Walsh; Phillip Andrew Futreal, PhD; Ignacio Wistuba, MD; Jack Roth; Zhang Jianjun; Emily Roarty, PhD; Lara Alvarez de Lacerda-Landry; Stephen G. Swisher, MD; Tina Cascone, MD, PhD; Gregory A. Lizee, PhD; John V. Heymach; Boris Sepesi, MD; Don Gibbons, MD; Chantale Bernatchez | Immune contexture; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P234 | NF-κB p50 deficient immature myeloid cell (p50-IMC) adoptive cell transfer activates the tumor microenvironment to slow tumor growth | Rahul Suresh, PhD; Theresa Barberi, PhD; David Barakat, PhD; Kenneth J. Pienta, MD; Alan D. Friedman, MD | Adoptive immunotherapy; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| P235 | STACT-TREX1: A novel tumor-targeting systemically-delivered STING pathway agonist demonstrates robust anti-tumor efficacy in multiple murine cancer models | Laura H. Glickman, PhD; Justin Skoble, PhD; Chris S. Rae, PhD; Anastasia M. Makarova, PhD; Marc A. D'Antonio; Andrew J. McGeehan; Christopher Thanos, PhD | Checkpoint blockade; Immune adjuvant; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P236 | Flower-code: A novel Immunotherapy target | Rajan Gogna, PhD, MS, MBA; Christopher Pelham; Taylor Parker; Esha Madan, PhD, MS, MBA; Carlos Carvalho, MD; Antonio Beltran; | Antibody; Carcinogenesis; Chemotherapy; Costimulation; Gene expression; Immune adjuvant; Immune tolerance; Pediatric tumors; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P237 | CAR-modified killer MSC targeting GD2-positive Ewing sarcoma | Giulia Golinelli, PhD; Massimo Dominici; Giulia Grisendi; Carlotta Spano; Filippo Rossignoli; Malvina Prapa; Angela d'Esposito | CAR T cells; Pediatric tumors; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P238 | Regulation of in vivo anti-tumor activity of adoptively transferred CAR-T cells using FDA approved small molecule drugs | Brian M. Dolinski, BS; Scott Heller, MS; Mara Inniss; Abhishek Kulkarni; Dan Jun Li, MD; Christopher Reardon; Dexue Sun; Karen Tran, MS; Michelle L. Ols, PhD; Jennifer L. Gori, PhD; Vipin Suri; Celeste Richardson; Steven Shamah, Ph.D. | Adoptive immunotherapy; CAR T cells; Gene expression; Leukemia/Lymphoma; T cell |
| P239 | Novel solid tumor gene therapy approach mediated by engineered Bifidobacterium longum generates efficient tumor-derived IL-12 expression and results in local and systemic anti-tumor immunity | Sheetal Raithatha; Umesh Ramachandran; Melissa Dennis; Elena Topchy; Steven Zhao; Alexander Graves; | Adoptive immunotherapy; Cytokine; Gene expression; Microbiome; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P240 | Autologous Epstein-Barr virus (EBV)-specific T cells (baltaleucel T): preliminary results from a multicenter, multinational phase 2 study for treatment of EBV-associated NK/T cell lymphoma | Kurt C. Gunter, MD; Yasuhiro Oki, MD; Won Seog Kim; Kirit Ardeshna, MB BChir MA MD FRCP FRCPath; Yi Lin, MD PhD; Jia Ruan, MD, PhD; Pierluigi Porcu, MD; Jonathan Brammer, MD; Eric Jacobsen, MD; Dok Hyun Yoon, MD; Cheolwon Suh, MD PhD; Felipe Suarez, MD PhD; John Radford, MD; Lihua E. Budde, MD PhD; JIN SEOK Kim, MD PhD; Gilles Salles, MD; Hun Ju Lee, MD; Catherine Bollard, MD; Arnaud Jaccard, MD PhD; Hye Jin Kang, MD PhD; Shannon Inman, BS; Maryann Murray; Katherine E. Combs, RN; Kurt C. Gunter, MD; Daniel Y. Lee, MD PhD; Ranjana Advani, MD; M. Rooney, PhD; Helen E. Heslop, MD | Adoptive immunotherapy; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell |
| P241 | Melanoma-derived human CD4+ tumor-infiltrating lymphocytes (TIL) demonstrate a functional response to autologous tumor | MacLean Hall; Autumn Joerger; Ellen Scott; Ben Schachner; Allison Richards; Valerie Stark; Jeani Rich; Amy M. Weber, .; Doris Wiener; Krithika N. Kodumudi, PhD; Matthew Beatty, PhD; Amod A. Sarnaik, MD; Shari A. Pilon-Thomas, PhD; | Adoptive immunotherapy; Cytokine; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P243 | Tumour infiltrating lymphocyte therapy: clinical outcomes in pre-treated metastatic melanoma patients and biomarker correlations | Manon Pillai, MB BS MD; Ryan Guest; Natallia Kirillova; Paul Lorigan; Michelle L. Le Brocq; John S. Bridgeman, BSc, MSc, PhD; Robert E. Hawkins, MD, PhD; | Adoptive immunotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| P244 | Reactive myelopoiesis triggered by lymphodepletion limits the efficacy of adoptive T cell therapy | Patrick Innamarato, B.S.; Shari A. Pilon-Thomas, PhD; Krithika N. Kodumudi, PhD; Amy M. Weber; Amod A. Sarnaik, MD; Doris Weiner; Jennifer Morse, MS; Michael Kidd; Patrick Verdugo | Adoptive immunotherapy; Chemotherapy; Clinical trial; Immune suppression; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P245 | Enrichment of rare antigen-specific CD8+ T cells directly from splenocytes improves output and throughput | Ariel Y. Isser; John Hickey, BS; Kayla Gee; Sebastian Salathe; Yi Dong; Jonathan P. Schneck, MD, PhD; | Adoptive immunotherapy; T cell |
| P246 | Targeting novel tumor-associated antigens with TCR-engineered T Cells | Mamta Kalra, PhD; Ali Mohamed, PhD; Zoe Coughlin; Thorsten Demberg, PhD; Amir Alpert, BS; Leoni Alten; Sebastian Bunk, PhD; Claudia Wagner; Jens Fritsche, PhD; Oliver Schoor, PhD; Agathe Bourgogne; Yannick Bulliard, PhD; Geoffrey Stephens; Dominik Maurer, PhD; Harpreet Singh, PhD; Carsten Reinhardt, MD, PhD; Tony Weinschenk; Steffen Walter, PhD | Adoptive immunotherapy; Clinical trial; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P247 | Potent ex vivo expanded, human CD34+ cord blood-derived natural killer cells for glioblastoma immunotherapy | Lin Kang, Ph.D.; Shuyang He; William van der Touw; Bhavani Stout; Valentina Rousseva; Rathna Ravishankar; Robert Hariri; Xiaokui Zhang; | Adoptive immunotherapy; Cytokine; NK/NK T cell; Solid tumors |
| P248 | IL-2, IL-15 and IL-21 expanded tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer | Dragan Kiselicki; Julia Karbach; Martin Rao, PhD; Ernest Dodoo; Evgueni Sinelnikov; Akin Atmaca; Markus Maeurer; Elke Jaeger | Adoptive immunotherapy; Immune contexture; Immune monitoring; Tumor infiltrating lymphocytes (TILs) |
| P249 | Glypican-1 (GPC-1) specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD1 antibody therapies | Daiki Kato, DVM; Tomonori Yaguchi, MD, PhD; Kenji Morii, MS; Satoshi Serada; Tetsuji Naka; Takayuki Nakagawa; Ryohei Nishimura; Yutaka Kawakami, MD PhD | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Solid tumors; T cell; Tumor antigens; Tumor microenvironment |
| P250 | Shorter ex vivo expansion of Th17 cells mediates potent anti-tumor regression in melanoma | Hannah Knochelmann; Michelle H. Nelson, PhD; Jacob S. Bowers; Megan Wyatt, MS; Aubrey S. Smith; Connor J. Dwyer, PhD; Chrystal M. Paulos, PhD | Adoptive immunotherapy; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P251 | Tumor-infiltrating lymphocytes (TIL) for the adoptive treatment of patients with pancreatic cancer | Joana Lérias, DVM; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Martin Rao, PhD; Nuno Couto; Davide Valentini; Mireia Castillo-Martin; Antonio Beltran; Evgueni Sinelnikov; Hans Hofmeister; Ana Vieira; Javier Martin-Fernandez; Andreia Maia; Dário Ligeiro; Carlos Carvalho; Dragan Kiselicki; Akin Atmaca; Julia Karbach; Elke Jäger; Markus Maeurer; Joana R. Lerias, PhD; | Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P252 | Fast quality gauging of tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer | Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Joana Lérias, DVM; Martin Rao, PhD; Mireia Castillo-Martin; Antonio Beltran; Evgueni Sinelnikov; Hans Hofmeister; Javier Martin-Fernandez; Andreia Maia; Dário Ligeiro; Carlos Carvalho; Dodoo Ernest; Dragan Kiselicki; Julia Karbach; Elke Jäger; Ana Vieira; Markus Maeurer; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; | Adoptive immunotherapy; Cytokine; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P253 | B cell structural diversity in early cultured tumor-infiltrating lymphocytes | Dario D. Ligeiro, PhD; Dário Ligeiro; Hélder Trindade; Joana Lérias, DVM; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Andreia Maia; Catarina V. de Oliveira; Javier Martin-Fernandez; Martin Rao, PhD; Carlos Carvalho, MD; Mireia Castillo-Martin; Markus Maeurer; Dário Ligeiro; | Adoptive immunotherapy; B cell; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P254 | Natural Killer cells propagated under pressurized culture conditions show enhanced tumor killing activity | James Lim; Ann Lu; Nick Wilson; Albert Wong | Adoptive immunotherapy; CAR T cells; Immune monitoring; Metabolism; NK/NK T cell; Stem cell/cancer-initiating cell; Solid tumors; Tumor microenvironment |
| P255 | Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors | Sylvie Rottey, MD; Mateusz Opyrchal, MD PhD; Kunle Odunsi, MD, PhD; Jean-Pascal Machiels, MD, PhD; Solmaz Sahebjam, MD; Leila Shaza, MD; Sandrine Aspeslagh; Marc Van den Eynde, MD; Jean-Luc Canon, MD; Javier Carrasco; Ahmad Awada; Eytan Breman, MSc; Panagiota A. Sotiropoulou, PhD; Sarah Snykers, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Bikash Verma, MD; Frédéric F. Lehmann, MD; Alain Hendlisz, MD | Adoptive immunotherapy; CAR T cells; Clinical study; Clinical trial; Solid tumors; Tumor microenvironment |
| P256 | Evaluation of therapeutic T cell manufacture using long amplicon TCRβ immune repertoire sequencing | Geoffrey M. Lowman, PhD; Lauren Miller, BS; Timothy Looney, PhD; Tor Espen Stav-Noraas; Reidun Hartberg, PhD; Hilde Almåsbak; Mark Andersen, PhD; Sjoerd H. van der Burg, PhD; Elizabeth (Els) ME. Verdegaal, PhD; Noel F. de Miranda, PhD | Adoptive immunotherapy; CAR T cells; Immune monitoring; Leukemia/Lymphoma; T cell |
| P257 | Natural Killer and TCR gamma-delta T-cells are present in the tumor microenvironment and can be expanded for adoptive immunotherapy for epithelial cancer | Andreia Maia; Joana Lérias; Catarina de Oliveira; Javier Martin-Fernandez; Georgia Paraschoudi, M.Sc.; Martin Rao, PhD; Dário Ligeiro; Tin Htwe Thin, Ph.D.; Ana Isabel Vieira; Carlos Carvalho, MD; Markus Maeurer; Mireia Castillo-Martin | Adoptive immunotherapy; Antibody; Biomarkers; Cytokine; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P258 | sd-rxRNA to enhance NK cell activity for adoptive cell transfer | Melissa Maxwell, MS; James Cardia; Dingxue Yan, PhD; Gerrit Dispersyn, PhD | Adoptive immunotherapy; Checkpoint blockade; Gene expression; NK/NK T cell |
| P259 | Regional delivery of chimeric antigen receptor (CAR)-engineered T cells with 4-1BB co-stimulation effectively targets TAG72-positive peritoneal ovarian tumors | John P. Murad, BS, MS; Anna K. Kozlowska, MSc, PhD; Maya Ramamurthy; Wen-Chung Chang, MS; Paul Yazaki, PhD; David Colcher, PhD; John Shively, PhD; Mihaela Cristea, MD; Stephen J. Forman, MD; Saul Priceman, BS PhD; | CAR T cells; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor evasion |
| P260 | Automated perfusion-based systems for research- and clinical-scale dendritic cell generation | Andrew Kozbial, BS, PhD; Lekhana Bhandary, BS, PhD; Shashi Murthy, BS, PhD | Dendritic cell; Monocyte/Macrophage; Neoantigens; Vaccine |
| P261 | Identification and pre-clinical development of tumour-reactive T-cell receptors from tumour-infiltrating lymphocytes | Natasha Myhill, MRes; John Bridgeman, Dr.; | Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P262 | AIM ACT, a novel nanoparticle-based technology that generates therapeutic numbers of functional tumor-specific CD8+ T cells with central and effector phenotype in 14 days | Mathias Oelke, Ph.D.; Sojung Kim; Juan Varela; Tatsuya Yoshida; Jeffrey S. Weber, MD, PhD; Lauren Suarez; Emily Lu; Celine Walmacq; Daniel Dembrow; Daniel Bednarik; Kenneth Carter, PhD; Kristi Jones; Scott P. Carmer, MBA; | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Dendritic cell; Leukemia/Lymphoma; Neoantigens; T cell; Targeted therapy; Tumor antigens |
| P263 | IL13RA2 as a new target for T-cell based therapies of melanoma brain metastases | Maria C. Ramello, PhD; Ismahene Benzaid, PhD; Maritza Lienlaf; Vincent Law; Nikhil I. Khushalani, MD; Amod A. Sarnaik, MD; Inna Smalley, PhD; Keiran S. Smalley, PhD; Peter A. Forsyth, MD; Daniel Abate-Daga, PhD | Adoptive immunotherapy; CAR T cells; Solid tumors |
| P264 | Identification of tyrosine phosphorylation sites in CD28 domain and their role in CAR-T cell function | Maria C. Ramello, PhD; Bin Fang, PhD; John Koomen, PhD; Eric Haura, MD; Daniel Abate-Daga, PhD | Adoptive immunotherapy; CAR T cells; Solid tumors |
| P265 | Inhibiting immune evasion in CNS tumors by reversing epigenetic gene silencing of chemoattractant cytokines | Nivedita M. Ratnam, PhD; Heather M. Sonnemann; Amber J. Giles, PhD; Mark R. Gilbert | Chemokine; Cytokine; Gene expression; T cell |
| P266 | Improving T cell functionality for adoptive cell transfer therapy in metastatic colon cancer | Sruthi Ravindranathan, PhD; Mohammad Raheel Jajja; Sruthi Ravindranathan, PhD; Christopher Petersen; Ramireddy Bommireddy; Periasamy Selvaraj; Lily Yang; Bassel El-rayes, MD; Brianna Flynn, MS; Edmund K. Waller, MD, PhD, FACP; Sruthi Ravindranathan, PhD; | Adoptive immunotherapy; Solid tumors |
| P267 | Hijacked CAR19 T cells have potent activity against solid tumors | Paul Rennert, PhD; Fay Dufort, PhD; Lihe Su, PhD; Lan Wu, PhD; Alyssa Birt; Roy Lobb, PhD; Christine Ambrose, PhD | CAR T cells; Leukemia/Lymphoma; Solid tumors; Tumor antigens |
| P268 | Heterogeneity of pancreatic cancer tumor-infiltrating T cells at the single cell level | Donastas Sakellariou-Thompson, BS; Aislyn Schalck; Mark Hurd, PhD; Gauri Varadhachary; Milind Javle, MD; Anirban Maitra, MBBS; Nicholas Navin, PhD; Cara Haymaker, PhD; Chantale Bernatchez | Gene expression; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P269 | Global phosphoproteomic analysis of chimeric antigen receptor and T cell receptor signaling enables design of modified receptors with distinct properties | Alexander I. Salter, BS; Richard G. Ivey; Anusha Rajan; Jacob J. Kennedy; Valentin Voillet, PhD; Jeffrey R. Whiteaker; Raphael Gottardo, PhD; Amanda G. Paulovich, MD, PhD; Stanley R. Riddell, MD | Adoptive immunotherapy; CAR T cells; Proteomics; T cell |
| P270 | A novel, human sdAb-based, CAR against CD33, effectively targets AML in vitro and in vivo, and spares hematopoietic stem cells | Dina Schneider, PhD; Ying Xiong, PhD; Peirong Hu; Darong Wu, MS; Weizao Chen; Tianlei Ying; Zhongyu Zhu; Dimiter Dimitrov, PhD; Boro Dropulic, PhD, MBA; Rimas J. Orentas, PhD | Adoptive immunotherapy; Antibody; CAR T cells; Leukemia/Lymphoma; Pediatric tumors; T cell; Tumor antigens |
| P271 | Titratable and reversible regulation of IL12 or IL15 with FDA-approved drugs enhances CAR-T therapy | Brian M. Dolinski, BS; Kutlu Elpek; Tucker Ezell; Michelle Fleury; Jennifer L. Gori, PhD; Jia Gwee; Scott Heller, MS; Mara Inniss; Abhishek Kulkarni; Meghan Langley, BS; Dan Jun Li, MD; Grace Olinger, MS; Michelle L. Ols, PhD; Benjamin Primack; Christopher Reardon; Michael Schebesta; Dexue Sun; Zoe Tarasiewicz, BA; Karen Tran, MS; Michael Briskin; Celeste Richardson; Vipin Suri; Steven Shamah, Ph.D. | CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P272 | A fully-closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens | Christine M. McInnis, PhD; Amy M. Shaw; Shawn P. Carey, PhD; Jonas Bruun, PhD; Rachel Klaski; Pengpeng Cao, PhD; Elisabeth Brown; Andy Rakestraw, PhD; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Thomas L. Andresen, PhD; FABIO FACHIN, PhD | Adoptive immunotherapy; Antigen presenting cells; Clinical trial; Cytokine; Dendritic cell; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P273 | T cells cultured in the presence of TLR9 agonist gain a CD25(high)CD39(low), pro-inflammatory phenotype and regress melanoma in vivo | Hannah Knochelmann; Connor J. Dwyer, PhD; Aubrey S. Smith; Aubrey S. Smith; Megan Wyatt, MS; Chrystal M. Paulos, PhD; Michelle H. Nelson, PhD; | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR |
| P274 | Functional screening of different anti-B7H6 CAR designs | Lorraine P. Springuel; Benjamin Demoulin; Martina Fontaine, PhD; Adam Hargreaves, Dr; Dorothée Daro; Jennifer Bolsée, PhD; Céline Jacques-Hespel; Valérie Steenwinckel, PhD; David E. Gilham, PhD; Sophie Agaugué, PhD | CAR T cells; Solid tumors; Tumor antigens |
| P275 | Pooling signaling and costimulatory domains in a flexible CARpool design | Lorraine P. Springuel; Amélie Velghe; Sophie AGAUGUE, PhD; David E. Gilham, PhD; Jennifer Bolsée, PhD | Adoptive immunotherapy; CAR T cells; Costimulation |
| P276 | Characterization of systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T-cells in synovial sarcoma (NCT01343043) | Justina Stadanlick; Indu Ramachandran, PhD; Daniel Lowther; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Svetlana Fayngerts; Daniel Nunez; Natalie Bath, MSc; Gareth Betts, PhD; Karen Chagin, MD; Thomas H. Faitg, PhD; Wayne Higgins; Malini Iyengar, PhD; Luca Melchiori; Siva Samavedam; Jonathan D. Silk, PhD; Alex J. Tipping, PhD; Trupti Trivedi, MS; Erin Van Winkle; Lilli Wang; Rafael Amado, MD; Gwendolyn K. Binder; Samik Basu, MD; Samik Basu, MD; | Adoptive immunotherapy; Clinical trial; Immune contexture; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P277 | Genetic modification of IL13Rα2-CAR T cells to express secretory or membrane-bound IL-15 enhances their anti-glioma activity without discernible differences | David H. Steffin, MD; Haley Houke; Tim Sauer, MD; Irina V. Balyasnikova, Ph.D.; Stephen Gottschalk; M. Rooney, PhD; Giedre Krenciute, PhD | CAR T cells; Cytokine; Solid tumors |
| P278 | Identification of senescent T-cell subsets that impact gene-engineered T cell manufacturing success and product consistency | Jeffrey J. Teoh, PhD; Daniel Cossette; Sara Cooper; Ryan P. Larson, PhD | Adoptive immunotherapy; Biomarkers; CAR T cells; Leukemia/Lymphoma; T cell |
| P279 | CRISPR/Cas9 enables the efficient production of allogeneic CAR-T cells engineered to contain multiple genome edits to enhance therapeutic T-cell function | Ashley Porras, BA; Dan Henderson; Sushant Karnik; Katie Levitsky, BS; Demetrios Kalaitzidis, Ph.D.; Jason Sagert, PhD; Zinkal Padalia, MS; Mary Lee Dequeant, PhD; melanie allen, BS; Hanspeter Waldner; Henia Dar, PhD; Chandirasegaran Massilamany, PhD; Paul Tetteh; Dakai Mu, BA; Elaine Huang, PhD; Thao Nguyen; Sarah Spencer, PhD; Kelly Maeng; Jonathan Terrett, PhD | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Solid tumors |
| P280 | IL-12 cytokine priming of low avidity tumor specific T cells enhances tumor clearance and prevents exhaustion | Christopher G. Tucker, BS; Jason Mitchell; Brian Fife | Adoptive immunotherapy; Checkpoint blockade; Cytokine; T cell |
| P281 | Endogenous MHC class II restricted CD4+ T cell responses to recurrent driver mutations in melanoma and non-small cell lung cancer (NSCLC) | Joshua R. Veatch, MD, PhD; Brenda Jesernig, MS; Sylvia Lee; Stanley R. Riddell, MD | Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P282 | Pathogen-reduced human platelet lysate as a serum replacement maintains CAR T cells in a less-differentiated phenotype associated with superior anti-tumor function | Alejandro Torres Chavez; Emanuele Canestrari, PhD; Christina T. Dann, Ph.D; Ann Leen; Juan Vera; Norihiro Watanabe, Ph.D; Norihiro Watanabe, Ph.D; | Adoptive immunotherapy; CAR T cells |
| P283 | Allogeneic CAR T-cells resistant to both T- and NK-cell cytotoxicity | Alan Williams; Laurent Poirot, PhD; Philippe Duchateau; brian Busser; julien Valton; Alexandre juillerat; Stephane depil; Sonal Temburni-Blake, MS | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell |
| P284 | Importance of the enzymatic activity of CD26 expressed on tumor-specific Th17 cells for adoptive cell therapy | Chrystal M. Paulos, PhD; Megan Wyatt, MS; Stefanie Bailey; Hannah Knochelmann; Aubrey S. Smith; Connor J. Dwyer, PhD; Michelle H. Nelson, PhD; | Adoptive immunotherapy; Gene expression; T cell |
| P285 | A clinical study on CD33-directed chimeric antigen receptor modified NK cells | Leiming Xia; Jing Zhang; Liu Liu; Bin Li; Tan Li; Yi Wang; Lin Yang; Yangyi Bao; Alfred Chang; Max S. Wicha, MD; Qiao Li, PhD | Adoptive immunotherapy; Clinical trial; Cytokine; Leukemia/Lymphoma; NK/NK T cell |
| P286 | Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer cells in pre-heavily treated NSCLC: a retrospective study | Lingdi Zhao; Lu Han; Yong Zhang; Tiepeng Li; Yonghao Yang; Wei Li; Yiman Shang; Hongwei Lin; Quanli Gao | Adoptive immunotherapy; Checkpoint blockade; Coinhibition |
| O15 | Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors | Kristin G. Anderson, PhD; Shannon K. Oda; Breanna Bates, BS; Madison G. Burnett; Edison Chiu, BS; Magdalia L. Suarez Gutierrez; Nicolas Garcia, BS; Andrew W. Daman; Philip D. Greenberg, MD; | Adoptive immunotherapy; Costimulation; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| O16 | Tscm-like CD8+ T-cells are associated with adoptive TIL therapy response and survival | Matthew Beatty, PhD; Benjamin Schachner; Autumn Joerger; Ellen Scott; Patrick Verdugo; John E. Mullinax, MD; Amod A. Sarnaik, MD; Shari A. Pilon-Thomas, PhD; | Adoptive immunotherapy; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs) |
| O17 | Infusion of TGFβ-resistant EBV-specific T-cells post cytoreductive chemotherapy is safe and associated with clinical benefit in patients with recurrent/metastatic NPC | Christopher DeRenzo, MD; Mamta Kalra; Carlos Ramos; Catherine Robertson; Huimin Zhang; Claudia Gerken; Olga Dakhova; Melinda Mata; Meng-Fen Wu; Hao Liu; Catherine Bollard; Zhuyong Mei; Adrian Gee; Bambi Grilley; Gianpietro Dotti, MD; Helen E. Heslop, MD; Malcolm Brenner; Cliona Rooney; Stephen Gottschalk | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell |
| O18 | Preliminary clinical data from a pilot study of NY-ESO-1c259T-cells in advanced myxoid/round cell liposarcoma | Sandra D'Angelo; Mihaela Druta; David A. Liebner, MD; Scott Schuetze; Brian Van Tine; William Tap; Cedrik Britten, MD; Karen Chagin, MD; Aisha N. Hasan, MBBS MD; Elliot Norry, MD; Trupti Trivedi, MS; Rafael Amado, MD | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
